344 related articles for article (PubMed ID: 9562584)
1. HIV-protease inhibitors.
Flexner C
N Engl J Med; 1998 Apr; 338(18):1281-92. PubMed ID: 9562584
[No Abstract] [Full Text] [Related]
2. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
[No Abstract] [Full Text] [Related]
3. HIV protease inhibitors.
Winslow DL; Otto MJ
AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
[No Abstract] [Full Text] [Related]
4. Cross-resistance within the protease inhibitor class.
Race E
Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
[No Abstract] [Full Text] [Related]
5. Antiviral treatment of HIV infection.
Thomas MG; Ellis-Pegler RB
N Z Med J; 1998 Sep; 111(1074):353-4. PubMed ID: 11039818
[No Abstract] [Full Text] [Related]
6. HIV therapeutics: past, present, and future.
Abu-ata O; Slim J; Perez G; Smith SM
Adv Pharmacol; 2000; 49():1-40. PubMed ID: 11013759
[No Abstract] [Full Text] [Related]
7. [HIV-1 protease inhibitors. Why, when, and how?].
Gatell JM
Enferm Infecc Microbiol Clin; 1998 Nov; 16(9):393-4. PubMed ID: 9887623
[No Abstract] [Full Text] [Related]
8. Antiretroviral therapies.
Owen WF
Clin Podiatr Med Surg; 1998 Apr; 15(2):227-39. PubMed ID: 9576051
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy: where are we?
Hammer SM; Yeni P
AIDS; 1998; 12 Suppl A():S181-8. PubMed ID: 9633001
[No Abstract] [Full Text] [Related]
10. Pharmacological exposure and the development of drug resistance in HIV.
Hoetelmans R
Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
[No Abstract] [Full Text] [Related]
11. Combination therapy in the management of HIV infection.
Vella S; Franca Pirillo M
Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():23-6. PubMed ID: 9003571
[No Abstract] [Full Text] [Related]
12. Virological failure and adherence to antiretroviral therapy in HIV-infected patients.
Rodríguez-Rosado R; Jiménez-Nácher I; Soriano V; Antón P; González-Lahoz J
AIDS; 1998 Jun; 12(9):1112-3. PubMed ID: 9662214
[No Abstract] [Full Text] [Related]
13. Protease inhibitors and mortality among children and adolescents infected with HIV-1.
Barbaro G
N Engl J Med; 2002 Mar; 346(13):1026-7; author reply 1026-7. PubMed ID: 11919316
[No Abstract] [Full Text] [Related]
14. Update of the drug resistance mutations in HIV-1: 2004.
Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
[No Abstract] [Full Text] [Related]
15. Strategies for protease inhibitor failure.
Proj Inf Perspect; 1997 Nov; (23):4-5. PubMed ID: 11365379
[TBL] [Abstract][Full Text] [Related]
16. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
Hicks C
AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
[TBL] [Abstract][Full Text] [Related]
17. Salvage therapy for patients failing their current antiretroviral regimen.
Albrecht MA
AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
[No Abstract] [Full Text] [Related]
18. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.
Erickson JW; Gulnik SV; Markowitz M
AIDS; 1999; 13 Suppl A():S189-204. PubMed ID: 10885776
[No Abstract] [Full Text] [Related]
19. Guidelines for the treatment of HIV.
Newsline People AIDS Coalit N Y; 1999 Jan; ():31-3. PubMed ID: 11367185
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
